For 3QFY2017 Lupin posted results much better than expected on sales and
OPM fronts. In sales, the company posted sales of Rs4,110cr v/s Rs4,000cr
expected yoy growth of 31.3%. The strong sales growth was aided by the USA
(contributed around 49.0%), which registered a yoy growth of 57.6%. On EBITDA
front, the company posted EBITDA of 25.9% (v/s 22.4% expected) v/s 20.2% in
3QFY2016. Consequently, PAT came in at Rs633.1cr (v/s Rs637.2cr expected) v/s
Rs529.6cr in 3QFY2016, growth of 19.5% yoy. We maintain our buy rating on
the stock.
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...